In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

Clinical Trials In 2019: Is Biopharma Ready To Tackle The Iron Triangle of Time, Cost and Quality?

The clinical trial embodies the hope and the hassle of biopharma’s mission to develop new drugs for patients. It is an endlessly imperfect process: C-suite calls for more efficiency and speed at lower cost has been the story for decades. But an In Vivo conversation with a leading expert on trial management pinpoints three key trends that suggest better days are ahead for this central pillar of the innovation imperative.

Clinical Trials Innovation BioPharmaceutical
Advertisement

Latest From Market Intelligence

Device/Diagnostics Quarterly Dealmaking Statistics, Q2 2019

Device financing totaled $2.3bn for Q2 2019, with the debt category bringing in the most money. Merger and acquisition deals reached an aggregate $9.1bn (a 25% increase from Q1), thanks mostly to 3M’s  $6.7bn takeover of Acelity and its KCI subsidiaries. Diagnostics/research financing, which totaled $2.4bn, showed a significant rise from the previous quarter, while diagnostics/research tools M&A values, at $233m, exhibited a steep decline.

Deals Market Intelligence

Deals In Depth: August 2019

Celgene was involved in the two largest alliances of August: one to divest a product to satisfy regulatory conditions of its acquisition by Bristol-Myers Squibb and the other to develop adoptive cell therapies. There was continued acquisition activity in the CDMO market as Cambrex was bought out by investment firm Permira. Biopharma and device funding were both down.

Deals Market Intelligence

Can Novartis Reclaim Pioneering Role In Transplantation?

Novartis is developing a new type of immunosuppressive agent, an anti-CD40 monoclonal antibody, which might allow organ transplants to last longer in recipients, reducing the pressure on transplant waiting lists and improving the long-term outlook for patients.

Clinical Trials Companies

International IP Arbitration – A Blessing Or A Bad Idea?

Medtech companies traditionally resolved disputes over IP rights before national courts, but more and more of them are now turning to international arbitration to protect their IP rights. Dorothee Schramm, a partner at Sidley Austin specializing in international commercial disputes, explains the benefits of this growing trend and the pitfalls to avoid.

Business Strategies Market Intelligence

Biopharma Quarterly Dealmaking Statistics, Q2 2019

Biopharma companies raised $12.4bn in Q2, largely from follow-on public offerings. In the latest mega-merger of the year, AbbVie spent $63bn on Allergan and its established portfolio. Many of the higher-valued alliances focused on the area of protein degradation.

Market Intelligence Deals

Investigating Big Pharma Licensing Trends

AstraZeneca emerged as big pharma’s most active dealmaker over the 2014-2018 period, thanks to a combined surge in both in-licensing and out-licensing agreements.

Deals Market Intelligence
See All
UsernamePublicRestriction

Register

Advertisement